NASDAQ:ALGS

Aligos Therapeutics Competitors

$21.63
+0.29 (+1.36 %)
(As of 04/13/2021 09:55 AM ET)
Add
Compare
Today's Range
$21.63
Now: $21.63
$21.63
50-Day Range
$19.10
MA: $23.66
$29.80
52-Week Range
$12.82
Now: $21.63
$37.51
Volume1 shs
Average Volume70,605 shs
Market Capitalization$825.03 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Aligos Therapeutics (NASDAQ:ALGS) Vs. NSTG, RLAY, RVMD, VCEL, EDIT, and SRNE

Should you be buying ALGS stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Aligos Therapeutics, including NanoString Technologies (NSTG), Relay Therapeutics (RLAY), Revolution Medicines (RVMD), Vericel (VCEL), Editas Medicine (EDIT), and Sorrento Therapeutics (SRNE).

Aligos Therapeutics (NASDAQ:ALGS) and NanoString Technologies (NASDAQ:NSTG) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Earnings & Valuation

This table compares Aligos Therapeutics and NanoString Technologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aligos TherapeuticsN/AN/AN/AN/AN/A
NanoString Technologies$125.57 million25.27$-40,700,000.00($1.93)-36.88

Aligos Therapeutics has higher earnings, but lower revenue than NanoString Technologies.

Profitability

This table compares Aligos Therapeutics and NanoString Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aligos TherapeuticsN/AN/AN/A
NanoString Technologies-53.47%-68.96%-24.15%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Aligos Therapeutics and NanoString Technologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aligos Therapeutics00403.00
NanoString Technologies01402.80

Aligos Therapeutics currently has a consensus target price of $35.75, suggesting a potential upside of 65.28%. NanoString Technologies has a consensus target price of $68.60, suggesting a potential downside of 3.62%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Aligos Therapeutics is more favorable than NanoString Technologies.

Institutional and Insider Ownership

98.3% of NanoString Technologies shares are owned by institutional investors. 4.2% of NanoString Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Aligos Therapeutics beats NanoString Technologies on 5 of the 8 factors compared between the two stocks.

Aligos Therapeutics (NASDAQ:ALGS) and Relay Therapeutics (NASDAQ:RLAY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Aligos Therapeutics and Relay Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aligos Therapeutics00403.00
Relay Therapeutics01502.83

Aligos Therapeutics currently has a consensus target price of $35.75, suggesting a potential upside of 65.28%. Relay Therapeutics has a consensus target price of $57.40, suggesting a potential upside of 82.69%. Given Relay Therapeutics' higher probable upside, analysts plainly believe Relay Therapeutics is more favorable than Aligos Therapeutics.

Institutional and Insider Ownership

98.4% of Relay Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Aligos Therapeutics and Relay Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aligos TherapeuticsN/AN/AN/AN/AN/A
Relay TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares Aligos Therapeutics and Relay Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aligos TherapeuticsN/AN/AN/A
Relay TherapeuticsN/AN/AN/A

Summary

Relay Therapeutics beats Aligos Therapeutics on 3 of the 4 factors compared between the two stocks.

Revolution Medicines (NASDAQ:RVMD) and Aligos Therapeutics (NASDAQ:ALGS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Revolution Medicines and Aligos Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Revolution Medicines00203.00
Aligos Therapeutics00403.00

Revolution Medicines presently has a consensus target price of $51.00, suggesting a potential upside of 33.89%. Aligos Therapeutics has a consensus target price of $35.75, suggesting a potential upside of 65.28%. Given Aligos Therapeutics' higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than Revolution Medicines.

Insider & Institutional Ownership

85.8% of Revolution Medicines shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Revolution Medicines and Aligos Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revolution Medicines$50.04 million55.86$-47,660,000.00N/AN/A
Aligos TherapeuticsN/AN/AN/AN/AN/A

Aligos Therapeutics has lower revenue, but higher earnings than Revolution Medicines.

Profitability

This table compares Revolution Medicines and Aligos Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Revolution Medicines-191.17%-32.25%-20.55%
Aligos TherapeuticsN/AN/AN/A

Summary

Aligos Therapeutics beats Revolution Medicines on 5 of the 7 factors compared between the two stocks.

Vericel (NASDAQ:VCEL) and Aligos Therapeutics (NASDAQ:ALGS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.

Profitability

This table compares Vericel and Aligos Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vericel0.12%0.13%0.10%
Aligos TherapeuticsN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations for Vericel and Aligos Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vericel02602.75
Aligos Therapeutics00403.00

Vericel presently has a consensus target price of $49.00, suggesting a potential downside of 16.99%. Aligos Therapeutics has a consensus target price of $35.75, suggesting a potential upside of 65.28%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than Vericel.

Insider & Institutional Ownership

93.1% of Vericel shares are owned by institutional investors. 4.3% of Vericel shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Vericel and Aligos Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vericel$117.85 million23.09$-9,660,000.00$0.18327.94
Aligos TherapeuticsN/AN/AN/AN/AN/A

Aligos Therapeutics has lower revenue, but higher earnings than Vericel.

Summary

Vericel beats Aligos Therapeutics on 7 of the 9 factors compared between the two stocks.

Editas Medicine (NASDAQ:EDIT) and Aligos Therapeutics (NASDAQ:ALGS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk.

Insider and Institutional Ownership

87.5% of Editas Medicine shares are held by institutional investors. 0.9% of Editas Medicine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Editas Medicine and Aligos Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Editas Medicine$20.53 million136.43$-133,750,000.00($2.68)-15.51
Aligos TherapeuticsN/AN/AN/AN/AN/A

Aligos Therapeutics has lower revenue, but higher earnings than Editas Medicine.

Analyst Recommendations

This is a summary of recent ratings for Editas Medicine and Aligos Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Editas Medicine34402.09
Aligos Therapeutics00403.00

Editas Medicine presently has a consensus target price of $50.10, suggesting a potential upside of 23.55%. Aligos Therapeutics has a consensus target price of $35.75, suggesting a potential upside of 65.28%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than Editas Medicine.

Profitability

This table compares Editas Medicine and Aligos Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Editas Medicine-99.62%-26.74%-16.38%
Aligos TherapeuticsN/AN/AN/A

Summary

Aligos Therapeutics beats Editas Medicine on 5 of the 8 factors compared between the two stocks.

Aligos Therapeutics (NASDAQ:ALGS) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

27.4% of Sorrento Therapeutics shares are held by institutional investors. 3.4% of Sorrento Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Aligos Therapeutics and Sorrento Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aligos TherapeuticsN/AN/AN/AN/AN/A
Sorrento Therapeutics$31.43 million62.55$-292,070,000.00($2.12)-3.30

Aligos Therapeutics has higher earnings, but lower revenue than Sorrento Therapeutics.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Aligos Therapeutics and Sorrento Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aligos Therapeutics00403.00
Sorrento Therapeutics00403.00

Aligos Therapeutics currently has a consensus price target of $35.75, suggesting a potential upside of 65.28%. Sorrento Therapeutics has a consensus price target of $28.75, suggesting a potential upside of 316.67%. Given Sorrento Therapeutics' higher probable upside, analysts plainly believe Sorrento Therapeutics is more favorable than Aligos Therapeutics.

Profitability

This table compares Aligos Therapeutics and Sorrento Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aligos TherapeuticsN/AN/AN/A
Sorrento Therapeutics-698.01%-314.06%-43.60%

Summary

Sorrento Therapeutics beats Aligos Therapeutics on 4 of the 7 factors compared between the two stocks.


Aligos Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$71.18+3.0%$3.08 billion$125.57 million-41.63
Relay Therapeutics logo
RLAY
Relay Therapeutics
1.8$31.42+4.3%$2.96 billionN/A0.00
Revolution Medicines logo
RVMD
Revolution Medicines
1.7$38.09+3.0%$2.88 billion$50.04 million0.00Insider Selling
News Coverage
Vericel logo
VCEL
Vericel
1.1$59.03+1.4%$2.68 billion$117.85 million-5,903,000.00Increase in Short Interest
Editas Medicine logo
EDIT
Editas Medicine
1.6$41.58+5.0%$2.66 billion$20.53 million-23.90
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$7.00+0.9%$1.95 billion$31.43 million-4.79News Coverage
bluebird bio logo
BLUE
bluebird bio
1.8$28.01+0.1%$1.88 billion$44.67 million-2.55
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.6$24.08+7.6%$1.81 billionN/A-11.25Decrease in Short Interest
Gap Up
NantKwest logo
NK
NantKwest
1.3$16.09+4.8%$1.76 billion$40,000.00-22.66
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.7$9.61+1.1%$1.69 billion$48.83 million-12.64
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.15+0.8%$1.59 billion$102.43 million-18.58Analyst Upgrade
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$71.94+1.3%$1.58 billionN/A-48.61
Immunovant logo
IMVT
Immunovant
1.8$15.25+0.1%$1.50 billionN/A-11.82Increase in Short Interest
AlloVir logo
ALVR
AlloVir
1.4$22.76+0.0%$1.48 billionN/A0.00Increase in Short Interest
REGENXBIO logo
RGNX
REGENXBIO
1.6$35.11+3.9%$1.43 billion$35.23 million-14.16Increase in Short Interest
Gap Down
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.2$30.93+1.6%$1.41 billionN/A0.00Insider Selling
Increase in Short Interest
News Coverage
Replimune Group logo
REPL
Replimune Group
1.5$29.09+0.9%$1.36 billionN/A-16.44News Coverage
Alector logo
ALEC
Alector
1.3$17.30+2.9%$1.34 billion$21.22 million-7.76
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$31.11+1.3%$1.32 billionN/A0.00Increase in Short Interest
Translate Bio logo
TBIO
Translate Bio
1.6$17.51+2.2%$1.29 billion$7.80 million-16.36
Ocugen logo
OCGN
Ocugen
1.1$6.73+0.7%$1.26 billionN/A-4.55Increase in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.65+0.4%$1.15 billionN/A-2.95
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$28.42+4.0%$1.12 billion$100.56 million0.00Increase in Short Interest
Mesoblast logo
MESO
Mesoblast
1.4$8.58+1.5%$1.10 billion$32.16 million-9.75Decrease in Short Interest
Vaxcyte logo
PCVX
Vaxcyte
1.7$20.13+0.1%$1.03 billionN/A0.00Increase in Short Interest
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$13.85+1.1%$997.28 million$356.07 million6.79Unusual Options Activity
News Coverage
Curis logo
CRIS
Curis
1.3$10.43+3.7%$990.24 million$10 million-12.72Increase in Short Interest
Gap Down
Scholar Rock logo
SRRK
Scholar Rock
1.5$28.50+2.3%$953.88 million$20.49 million-11.83Increase in Short Interest
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$24.71+1.2%$944.03 millionN/A0.00Analyst Report
News Coverage
Gap Down
Cortexyme logo
CRTX
Cortexyme
1.3$32.98+3.3%$942.12 millionN/A-13.74Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.30+2.2%$894.42 millionN/A-4.18Increase in Short Interest
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$9.01+0.7%$887.01 million$250,000.00-7.09News Coverage
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$19.30+0.0%$885.72 million$42.74 million-214.44Increase in Short Interest
News Coverage
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$18.18+1.3%$863.74 million$69.89 million-4.34
Passage Bio logo
PASG
Passage Bio
1.8$16.33+2.1%$860.76 millionN/A0.00Increase in Short Interest
Gap Down
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$22.30+1.2%$840.16 millionN/A-9.21Analyst Report
Increase in Short Interest
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.51+0.8%$811.44 million$2.51 million-3.95
Cellectis logo
CLLS
Cellectis
1.3$19.45+4.1%$798.28 million$22.99 million-10.35
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.5$4.95+0.4%$772.67 million$1.12 million-5.00Increase in Short Interest
Inhibrx logo
INBX
Inhibrx
1.6$20.67+4.0%$749.30 millionN/A0.00Decrease in Short Interest
Gap Down
Harpoon Therapeutics logo
HARP
Harpoon Therapeutics
1.5$20.02+1.1%$656.00 million$5.78 million-9.40Increase in Short Interest
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.85+2.9%$624.08 million$14.75 million-2.51Increase in Short Interest
Gap Down
Athira Pharma logo
ATHA
Athira Pharma
2.2$17.02+1.3%$623.62 millionN/A0.00Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.37+2.8%$614.74 million$9.86 million-9.10
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.5$29.30+2.5%$600.74 millionN/A0.00Lockup Expiration
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.17+0.7%$578.97 million$13.29 million-9.34
Compugen logo
CGEN
Compugen
1.4$8.49+3.3%$561.73 million$17.80 million-22.95News Coverage
Agenus logo
AGEN
Agenus
1.6$2.65+0.8%$547.53 million$150.05 million-2.43
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.0$20.67+0.9%$533.23 millionN/A-5.96News Coverage
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.8$8.42+1.0%$527.92 millionN/A-1.23
This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.